liraglutide semaglutide tirzepatide Comparing GLP-type therapies for weight loss in those without diabetes. Two glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (#semaglutide and # liraglutide) and one dual agonist (#tirzepatide) have been FDA-approved for #weightloss in adults Tirzepatide and Injectable Semaglutide Correlated

Clinical trials have shown strong weight loss results in adults, but data on nursing individuals and the transfer of the drug into breast milk remain limited

By activating both GLP-1 and GIP receptors, it significantly reduces appetite and prolongs digestion, helping you feel full for longer

Taking Mounjaro requires careful monitoring for GLP-1 overexposure which may cause pancreatitis (inflammation of the pancreas), especially following a bariatric (weight loss) surgery

Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Zepbound during pregnancy

The SURMOUNT program focused on weight management in people without diabetes